Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Challenges and treatment of CNS metastases in NSCLC

Sanjay Popat • 19 Oct 2018
ESMO 2018
Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib
ALTA-1L

Sanjay Popat, PhD, MBBS, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the challenges and treatment of CNS metastases in non-small cell lung cancer from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Sanjay Popat

3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023
0:34
VJOncology at BTOG 2023
Sanjay Popat • 28 Apr 2023

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals